REFERENCES
- Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008;8:339–347
- Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol. 2006;34:365–374
- Ahmadi-Simab K, Lamprecht P, Nölle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–1088
- Chauhan S, Kamal A, Thompson RN, et al. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol. 2009;93:984–985
- Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223–225
- Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542
- Onal S, Kazokoglu H, Koc A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm. 2008;16:230–232
- Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–198
- Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35–39
- Akpek EK, Thome JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology 2004;111:501–506
- Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti CD20) experience. Ann Rheum Dis. 2003;62:55–59
- Usui Y, Parikh J, Goto H, et al. Immunopathology of necrotising scleritis. Br J Ophthalmol. 2008;92:417–419
- Dörner T, Isenberg D, Jayne D, et al. Current status on B cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009;9:82–89
- Piccio L, Naismith R, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67:707–714
- Takemura S, Klimiuk P, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710–4718
- Kurz PA, Suhler EB, Choi D, et al. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol. 2009;93:546–548
- Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15:e2–e16